EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%
Jamnagar’s contributions towards wellness will get a global identity with WHO’s Global Centre for Traditional Medicine
Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
The company performed particularly well in operational eco-efficiency, environmental and social reporting
Company working on COVID vaccine INO 4800
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come
Inspection included drug device combinations covering our recent filing in nasal sprays domain
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
Subscribe To Our Newsletter & Stay Updated
